Successful Treatment of Pansclerotic Morphea with Imatinib Mesylate in a Pediatric Patient

Received: Jan 09, 2013 Accepted: Jan 16, 2013 Ann Paediatr Rheum 2013; 2:43-49 DOI: 10.5455/apr.011620131348 Introduction Juvenile localized scleroderma ( JLS) is a childhood condition characterized by thickening of the skin. A variety of clinical subtypes have been described, differentiated by the size, shape, and location of skin involvement as well as the presence or absence of extra-cutaneous manifestations. These forms include linear scleroderma, plaque morphea, en coup de sabre and pansclerotic or generalized morphea [1-3]. JLS is a rare condition with a reported incidence of 3.4 cases per million. JLS is regarded as an autoimmune disease with unknown etiology or genetic risk factors [4]. In some cases incidental associations were reported involving poAbstract